Latest news with #SlingshotBiosciences
Business Wire
28-05-2025
- Business
- Business Wire
Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets
EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, a leader in precision-engineered cell mimics, has appointed Glenn Bilawsky as Chief Executive Officer. He succeeds Founder and former CEO Jeffrey Kim, PhD, who will remain actively involved as a Senior Advisor and Board Director. This transition is a strategic inflection point as Slingshot scales to meet rising global demand for cell mimics as standardized, reliable alternatives to biological controls. The widespread adoption of its TruCytes™ and SpectraComp ® products across research, clinical trials, diagnostics, and cell therapy applications is driving the company to expand its commercial footprint, industry partnerships, and advance regulatory-grade solutions. 'Slingshot is transforming how scientists in diagnostic, and therapeutic research and development access and apply cellular controls,' said Glenn Bilawsky, CEO. 'Jeff has built a remarkable company rooted in scientific excellence. I'm excited to build on that foundation—scaling the commercial team and focusing our portfolio to ensure our solutions maintain their position as the gold standard of cell-based controls used in regulated and research workflows.' Bilawsky brings decades of success and leadership in scaling life science, contract research, and analytical laboratory service companies focused on biomarker development. His appointment will accelerate Slingshot's momentum and the achievement of its mission to replace traditional biological reference materials with scalable, customizable and cost-effective cell mimic controls. Dr. Kim, who invented and led the development of Slingshot's core technologies, emphasized continuity in the company's mission: 'I'm proud of how far Slingshot has come. Glenn brings a remarkable track record of success and his leadership will unlock our next phase of growth. I am committed to the continued support of the company and look forward to working with Glenn in this next phase of the business.' About Slingshot Biosciences Slingshot Biosciences develops cell mimics for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf customizable solution for cell-like reagents that are stable and targeted toward a range of indications and markets.
Yahoo
28-05-2025
- Business
- Yahoo
Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets
EMERYVILLE, Calif., May 28, 2025--(BUSINESS WIRE)--Slingshot Biosciences, a leader in precision-engineered cell mimics, has appointed Glenn Bilawsky as Chief Executive Officer. He succeeds Founder and former CEO Jeffrey Kim, PhD, who will remain actively involved as a Senior Advisor and Board Director. This transition is a strategic inflection point as Slingshot scales to meet rising global demand for cell mimics as standardized, reliable alternatives to biological controls. The widespread adoption of its TruCytes™ and SpectraComp® products across research, clinical trials, diagnostics, and cell therapy applications is driving the company to expand its commercial footprint, industry partnerships, and advance regulatory-grade solutions. "Slingshot is transforming how scientists in diagnostic, and therapeutic research and development access and apply cellular controls," said Glenn Bilawsky, CEO. "Jeff has built a remarkable company rooted in scientific excellence. I'm excited to build on that foundation—scaling the commercial team and focusing our portfolio to ensure our solutions maintain their position as the gold standard of cell-based controls used in regulated and research workflows." Bilawsky brings decades of success and leadership in scaling life science, contract research, and analytical laboratory service companies focused on biomarker development. His appointment will accelerate Slingshot's momentum and the achievement of its mission to replace traditional biological reference materials with scalable, customizable and cost-effective cell mimic controls. Dr. Kim, who invented and led the development of Slingshot's core technologies, emphasized continuity in the company's mission: "I'm proud of how far Slingshot has come. Glenn brings a remarkable track record of success and his leadership will unlock our next phase of growth. I am committed to the continued support of the company and look forward to working with Glenn in this next phase of the business." About Slingshot Biosciences Slingshot Biosciences develops cell mimics for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf customizable solution for cell-like reagents that are stable and targeted toward a range of indications and markets. View source version on Contacts Brint Rodenpr@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
06-05-2025
- Business
- Associated Press
Slingshot Biosciences Debuts TruCytes™ Potency—Cell Mimics for Scalable, Reproducible CAR-T Potency Assays
EMERYVILLE, Calif.--(BUSINESS WIRE)--May 6, 2025-- Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency , a new class of biomarker cell mimics specifically designed for functional CAR-T potency assays. TruCytes Potency cell mimics offer a customizable, scalable, and efficient alternative to cell line target cells. This helps CAR-T developers accelerate assay validation and lot release, while avoiding the operational burden, variability and chain-of-custody challenges of custom cell lines. 'As cell and gene therapies continue to revolutionize medicine, the demand for smarter, more scalable cell solutions is only growing,' said Jeff Kim, CEO of Slingshot Biosciences. 'With TruCytes Potency, we're giving cell therapy developers a new tool for greater consistency, efficiency, and confidence. This launch marks a key milestone in our mission to make precision therapeutics a reality.' Initial data on TruCytes Potency will be presented on May 8th at the 31st annual International Society for Cell & Gene Therapy (ISCT) Conference in New Orleans, Louisiana. During the oral presentation 'Cell Mimics As High Precision Controls for CGT Analytics and Potency Assays' Robyn Hall, Ph.D., Cell Therapy Specialist at Slingshot Biosciences, will highlight the performance of TruCytes Potency CD19 and BCMA cell mimics in comparison to tumor cell lines. 'Validating a reliable potency assay remains one of the biggest hurdles in CAR-T development,' said Hall. 'Traditional options like engineered cell lines introduce challenges—variability, long timelines, and regulatory risks. We are excited to bring the consistency of TruCytes cell mimics to potency assessments, enabling cell therapy manufacturers to generate reproducible quality attributes reflecting the function of their products.' TruCytes Potency cell mimics are now available as a customizable solution through Slingshot Biosciences. TruCytes Potency cell mimics can be customized for a range of clinically relevant antigens to meet specific program needs. To learn more or begin designing a TruCytes Potency solution, visit: About Slingshot Biosciences Slingshot Biosciences develops cell mimics for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf customizable solution for cell-like reagents that are stable and targeted toward a range of indications and markets. . View source version on CONTACT: Brint Roden [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA LOUISIANA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL GENETICS HEALTH SOURCE: Slingshot Biosciences Copyright Business Wire 2025. PUB: 05/06/2025 10:07 AM/DISC: 05/06/2025 10:07 AM
Business Wire
06-05-2025
- Business
- Business Wire
Slingshot Biosciences Debuts TruCytes™ Potency—Cell Mimics for Scalable, Reproducible CAR-T Potency Assays
EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell mimics specifically designed for functional CAR-T potency assays. TruCytes Potency cell mimics offer a customizable, scalable, and efficient alternative to cell line target cells. This helps CAR-T developers accelerate assay validation and lot release, while avoiding the operational burden, variability and chain-of-custody challenges of custom cell lines. "As cell and gene therapies continue to revolutionize medicine, the demand for smarter, more scalable cell solutions is only growing,' said Jeff Kim, CEO of Slingshot Biosciences. 'With TruCytes Potency, we're giving cell therapy developers a new tool for greater consistency, efficiency, and confidence. This launch marks a key milestone in our mission to make precision therapeutics a reality." Initial data on TruCytes Potency will be presented on May 8th at the 31st annual International Society for Cell & Gene Therapy (ISCT) Conference in New Orleans, Louisiana. During the oral presentation 'Cell Mimics As High Precision Controls for CGT Analytics and Potency Assays' Robyn Hall, Ph.D., Cell Therapy Specialist at Slingshot Biosciences, will highlight the performance of TruCytes Potency CD19 and BCMA cell mimics in comparison to tumor cell lines. "Validating a reliable potency assay remains one of the biggest hurdles in CAR-T development," said Hall. "Traditional options like engineered cell lines introduce challenges—variability, long timelines, and regulatory risks. We are excited to bring the consistency of TruCytes cell mimics to potency assessments, enabling cell therapy manufacturers to generate reproducible quality attributes reflecting the function of their products." TruCytes Potency cell mimics are now available as a customizable solution through Slingshot Biosciences. TruCytes Potency cell mimics can be customized for a range of clinically relevant antigens to meet specific program needs. To learn more or begin designing a TruCytes Potency solution, visit: About Slingshot Biosciences Slingshot Biosciences develops cell mimics for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf customizable solution for cell-like reagents that are stable and targeted toward a range of indications and markets.
